GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » EV-to-EBIT

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) EV-to-EBIT : 0.03 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Skystar Bio-Pharmaceutical Co's Enterprise Value is $0.42 Mil. Skystar Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2014 was $13.97 Mil. Therefore, Skystar Bio-Pharmaceutical Co's EV-to-EBIT for today is 0.03.

The historical rank and industry rank for Skystar Bio-Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

SKBI's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.115
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Skystar Bio-Pharmaceutical Co's Enterprise Value for the quarter that ended in Sep. 2014 was $39.67 Mil. Skystar Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2014 was $13.97 Mil. Skystar Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2014 was 35.21%.


Skystar Bio-Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co EV-to-EBIT Chart

Skystar Bio-Pharmaceutical Co Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.40 3.83 1.19 0.72 2.15

Skystar Bio-Pharmaceutical Co Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.51 2.15 3.53 4.59 2.84

Competitive Comparison of Skystar Bio-Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skystar Bio-Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's EV-to-EBIT falls into.



Skystar Bio-Pharmaceutical Co EV-to-EBIT Calculation

Skystar Bio-Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.420/13.967
=0.03

Skystar Bio-Pharmaceutical Co's current Enterprise Value is $0.42 Mil.
Skystar Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skystar Bio-Pharmaceutical Co  (GREY:SKBI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Skystar Bio-Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2014 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2014 ) =EBIT / Enterprise Value (Q: Sep. 2014 )
=13.967/39.6651089
=35.21 %

Skystar Bio-Pharmaceutical Co's Enterprise Value for the quarter that ended in Sep. 2014 was $39.67 Mil.
Skystar Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skystar Bio-Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN
Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines